Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner

Atherosclerosis

Volumn 158, Issue 1, 2001, Pages 183-193

  Pedro Botet, Juan ^a,b   Schaefer, Ernst J ^a,b   Bakker Arkema, Rebecca G ^c   Black, Donald M ^c   Stein, Evan M ^d   Corella, Dolores ^b   Ordovas, Jose M ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY   (United States)

^c PFIZER INC   (United States)

^d Pharmaceutical Product Development   (United States)

Author keywords

Apolipoprotein E; Genetic polymorphism; HMG CoA reductase inhibitor; Lipoproteins, HDL cholesterol; Lipoproteins, LDL cholesterol; Pharmacogenetics; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN E; ATORVASTATIN; DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; TRIACYLGLYCEROL;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG RESPONSE; FEMALE; GENE LOCUS; GENOTYPE; HETEROZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS E; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HEPTANOIC ACIDS; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPIDS; LIPOPROTEINS; LOVASTATIN; MALE; MIDDLE AGED; PYRROLES; SEX FACTORS;

EID: 0034909515     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00410-5     Document Type: Article

References (37)

1. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
2. Primary and secondary prevention of coronary artery disease: A follow-up on clinical controlled trials
3. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males
4. Comparison of one year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia
5. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia
6. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
7. A brief review paper of the efficacy and safety of atorvastatin in early clinical trials
8. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
9. Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes
10. Atorvastatin, a new HMG-CoA reductase inhibitor as monotherapy and combined with colestipol
11. Genes, variation of cholesterol and fat intake and serum lipids
12. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology
13. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein
14. Identification and characterization of a new human gene (APOC4) in the apolipoprotein E, C-I, and C-II gene locus
15. Apolipoprotein E polymorphism and atherosclerosis
16. Human apolipoprotein E: The complete amino acid sequence
17. Apolipoprotein E metabolism in normolipoproteinemic human subjects
18. Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels: Results from the Framingham offspring study
19. Apolipoprotein E polymorphism and plasma cholesterol response to probucol
20. Effects of probucol on plasma lipids and lipoproteins in familial hypercholesterolemic patients with or without apolipoprotein E4
21. Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy
22. Influence of apolipoprotein E polymorphism on bezafibrate treatment response in dyslipidemic patients
23. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism
24. Effect of apolipoprotein E polymorphism and Xbal polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia
25. The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia
26. Influence of apoE polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia
27. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy
28. A simple salting out procedure for extracting DNA from human nucleated cells
29. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI
30. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: Prediction of response by baseline lipids, apoE genotype, lipoprotein(a) and insulin
31. Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia
32. High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia
33. Comparison of statins in hypertriglyceridemic
34. The genetics of serum lipid responsiveness to dietary interventions
35. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study
36. Cholesterol absorption and synthesis related to low density lipoprotein metabolism during varying cholesterol intake in men with different apoE phenotypes
37. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype